Axonis Therapeutics

Axonis

This biotechnology company develops oral small molecule therapies targeting the KCC2 protein to treat patients with epilepsy, chronic pain and spinal cord injuries.

Neurosciences

This company develops precision sodium channel therapeutics to treat patients with neurological conditions such as genetic epilepsy and chronic neuropathic pain.

iQure Pharma

This clinical-stage biotech company develops astrocyte-targeted therapeutics to restore glutamate balance for patients with central nervous system disorders such as epilepsy and Parkinson's disease.

Pano Therapeautics

This biotechnology company develops small molecule drugs targeting mitochondrial ion channels to treat neurodevelopmental disorders and complex diseases of aging.

EpilepsyGTx

This company develops precision gene therapies for patients with focal refractory epilepsy to provide seizure freedom.

Neumirna Therapeutics

This biotechnology company develops microRNA-based therapies to treat patients with neurological disorders, including drug-resistant epilepsy and Parkinson's disease.

Kynexis

This clinical-stage biotechnology company develops precision therapeutics and small-molecule inhibitors to treat cognitive impairment in patients with schizophrenia and other neurological disorders.

NeurOdys Therapeutics

This biotechnology company develops small molecule therapies for patients with neurodegenerative conditions such as Alzheimer's and Parkinson's diseases.